Rhythm Pharmaceuticals, Inc. develops precision medicines for patients with rare neuroendocrine diseases, focusing on conditions related to the melanocortin-4 receptor (MC4R) pathway. Its lead product, IMCIVREE® (setmelanotide), is FDA-approved for treating severe obesity due to POMC and LEPR deficiencies, as well as Bardet-Biedl syndrome (BBS). The company conducts clinical trials to advance its therapies and operates primarily in North America and Europe.
